产品详情
In vitro (25°C) | DMSO | 19 mg/mL (79.73 mM) | |
Water | Insoluble | ||
Ethanol | 2 mg/mL (8.39 mM) | ||
In vivo | 5% DMSO+40%PEG 300+ 5% Tween80 + ddH2O | 0.4 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 41.97 mL | 209.84 mL | 419.67 mL |
0.5 mM | 8.39 mL | 41.97 mL | 83.93 mL |
1 mM | 4.2 mL | 20.98 mL | 41.97 mL |
5 mM | 0.84 mL | 4.2 mL | 8.39 mL |
*The above data is based on the productmolecular weight 238.28. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A12437 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 238.28 |
Formula | C15H14N2O |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 204005-46-9 |
Synonyms | SU-5416, SU5416 |
SMILES | CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C |
产品标签
Product Questions
Product Questions
Brivanib (BMS-540215)
Brivanib (BMS-540215)是一种VEGFR-2抑制剂,IC50为25 nM,Ki为26 nM。
Buflomedil HCl
Buflomedil HCl是一种用于治疗外周血管疾病的血管活性剂。
BMS-817378
BMS-817378是Met/VEGFR-2双重抑制剂BMS-794833的新型前药。
Raf265 derivative
Raf265 derivative是Raf265的衍生物,Raf265是一种口服,高度选择性的RAF和VEGFR激酶抑制剂,IC50为5至10μM。
Bibf1120 (Nintedanib)
Bibf1120 (Nintedanib)是一种新型的三联血管激酶抑制剂,可同时抑制三种生长因子受体:VEGFR,PDGF和FGFR。